Smarter radiation planning aims to boost liver tumor attack while sparing healthy tissue

NCT ID NCT07669727

Not yet recruiting Disease control Sponsor: Boston Scientific Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study tests a new planning method called multicompartment dosimetry (MCD) for TheraSphere, a treatment that delivers tiny radioactive beads to liver tumors. The goal is to give a higher radiation dose to the tumor while protecting healthy liver. Researchers will enroll 140 people with a single, untreated liver tumor to see if this approach is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TheraSphere Microspheres (radioactive glass spheres)
What this could lead to: If successful, this could improve how doctors plan radiation for liver cancer, potentially leading to better tumor control with fewer side effects.
What could go wrong: This is a single-arm study with no comparison group, so results may not prove superiority over standard planning. The higher radiation dose could also increase liver damage risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.